Diamondback capital liquidating

14-Jul-2016 08:36

Beginning in 2008, many observers remarked that the 2004 change to the SEC's net capital rule permitted investment banks to increase their leverage and this played a central role in the financial crisis of 2007-2009.

This position appears to have been first described by Lee A.

By Jason Napodano, CFA & Aafia Chaudhry, MD Shares of Trius Therapeutics (NASDAQ: TSRX) have been under pressure over the past three months, down nearly 30% from the highs in mid-September 2012.

We decided to delve into why the shares are down over this period by putting on our bear-caps and coming up with reasons to sell the stock.

Her experiences include risk managing multi-billion dollar institutional hedge fund platform and fund investments, corporate pension plans, liquid alternatives, bank-owned life insurance policies and structured investment vehicles.

Below we discuss each reason and then provide the counterpoint bullish argument.

Reason # 1: Narrow Label Trius’ existing phase 3 program with tedizolid is testing the drug only in acute bacterial skin and skin structure infections (ABSSSI).

Ryan Abrams is Assistant Portfolio Manager at Wisconsin Alumni Research Foundation, the private nonprofit technology transfer office of the University of Wisconsin-Madison.

In this role he is responsible for manager research and due diligence for strategies focused on marketable investments. Abrams also provides analytical support for the asset allocation of WARF’s investment portfolio.

Her experiences include risk managing multi-billion dollar institutional hedge fund platform and fund investments, corporate pension plans, liquid alternatives, bank-owned life insurance policies and structured investment vehicles.

Below we discuss each reason and then provide the counterpoint bullish argument.

Reason # 1: Narrow Label Trius’ existing phase 3 program with tedizolid is testing the drug only in acute bacterial skin and skin structure infections (ABSSSI).

Ryan Abrams is Assistant Portfolio Manager at Wisconsin Alumni Research Foundation, the private nonprofit technology transfer office of the University of Wisconsin-Madison.

In this role he is responsible for manager research and due diligence for strategies focused on marketable investments. Abrams also provides analytical support for the asset allocation of WARF’s investment portfolio.

This would place the drug at a disadvantage against generic vancomycin and Pfizer’s (NYSE: PFE) Zyvox (linezolid), also approved for use in lung infections, and Cubist’s (NASDAQ: CBST) Cubicin (daptomycin), also approved for use in bacteremia.